Dana-Farber Cancer Institute

What Dana-Farber Cancer Institute does

Dana-Farber Cancer Institute is a Boston-based, 501(c)(3) nonprofit cancer research and treatment organization founded in 1947 by Sidney Farber. It operates a multi-site clinical-care platform anchored by two main campuses in the Longwood Medical Area and Chestnut Hill, Massachusetts, plus eight community-based satellite cancer centers across Massachusetts and southern New Hampshire (with a ninth at Attleboro scheduled to open August 2026), and an International Patient Services program that reaches 130+ countries. The institute delivers multidisciplinary adult and pediatric oncology care through flagship clinical collaborations — the Dana-Farber Brigham Cancer Center with Brigham and Women's Hospital, and the Dana-Farber/Boston Children's Cancer and Blood Disorders Center with Boston Children's Hospital — and is building a $1.8 billion, 300-bed standalone adult cancer hospital in partnership with Beth Israel Lahey Health, scheduled to open in 2031. It is a Harvard Medical School teaching affiliate, an NCI-designated Comprehensive Cancer Center, an NCCN member, and consistently ranked #1 in cancer care in New England by U.S. News & World Report (2025-2026).

Dana-Farber's underlying technology platform combines an integrated electronic medical record spanning Mass General Brigham's Patient Gateway, Boston Children's MyChildren's, and Beth Israel Lahey Health's MyBILH Chart portals with proprietary AI tooling. The most notable in-house capabilities are the open-source MatchMiner AI clinical-trial matching platform (402 enrollments facilitated, 55-day median reduction in time-to-consent, 2026 Hearst Health Prize finalist), the personalized NeoVax/NeoVaxMI cancer-vaccine program with AI-guided neoantigen selection, the FaceAge computer-vision survival-prediction tool, the A-STEP clinicogenomic predictive model, the BRIDGE-SIC LLM pilot for patient-goals summarization, and a founding role in the Cancer AI Alliance. Research collaborations with 10x Genomics, Broad Clinical Labs, Ignite Proteomics, Precede Biosciences, and others extend its spatial-omics, proteomic, and liquid-biopsy capabilities, while 1,200+ active clinical trials annually feed a clinicogenomic data flywheel.

The institute's revenue is diversified across four streams: insurance reimbursement and patient billing (commercial insurers, Medicare Advantage, MassHealth, ConnectorCare), federal and foundation research grants (notably a $12M NIH SPORE and $11M Break Through Cancer grant), philanthropic donations and major gifts (including a $50M Yawkey Foundation gift in June 2026 and a $50M Bekenstein/Lavine families gift in February 2026), and event-based fundraising (the Pan-Mass Challenge raised $78M in the most recent year and over $1.125B since 1980, accounting for 67% of Jimmy Fund revenue). Pricing is determined by negotiated in-network rates with patient responsibility including copays, deductibles, and coinsurance; a self-service online cost-estimate tool is offered via Patient Gateway and a need-based financial-assistance program is available. Capital expansion is funded in part by a $1.29B tax-exempt bond offering completed in March 2026.

Name

Dana-Farber Cancer Institute

Legal name

Dana-Farber Cancer Institute, Inc.

Website

https://dana-farber.org

Company type

Private

Founded year

1947

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Dana-Farber Cancer Institute is a Boston-based 501(c)(3) nonprofit founded in 1947 that provides multidisciplinary adult and pediatric cancer care and runs 1,200+ clinical trials across two main campuses, eight community satellites, and International Patient Services reaching 130+ countries.

Ownership category

akta.pro rank

Product category

Specialty Cancer Hospital and Research Center

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical and Diagnostic Laboratories (62151), General Medical and Surgical Hospitals (622110)

SIC

Services-Hospitals (8060), Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Medical Oncology (HLAKAFAB), Breast Oncology (HLAKAFAJ), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Cancer treatment services
• Oncology research
• Clinical trials
• Pediatric oncology
• Precision medicine

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices13 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Insurance Reimbursement and Patient Billing: Primary revenue from clinical services billed to commercial insurers (Aetna, BCBS, Cigna, Harvard Pilgrim, UnitedHealthcare, etc.), Medicare Advantage, MassHealth, ConnectorCare plans, and patient out-of-pocket payments including copays, deductibles, and coinsurance; billed through Patient Gateway and MyBILH Chart portals.
2. Philanthropic Donations and Major Gifts: Major-gift philanthropy including the Yawkey Foundation $50M grant, Elaine and Eduardo Saverin Foundation $20M grant, Bekenstein/Lavine families (largest single gift in history), DeGregorio Family Foundation $300K, and broad donor base through Jimmy Fund, Giving Societies, and tribute gifts.
3. Fundraising Event Proceeds: Annual proceeds from signature fundraising events including the Pan-Mass Challenge (which raised $78M in the most recent year, with over $1.125B raised since 1980), the Jimmy Fund Walk, Swim Across America, and Hyundai-presented events.
4. Government and Research Grants: Federal research grants including a $12M NIH SPORE grant for breast cancer research via Dana-Farber/Harvard Cancer Center, plus Break Through Cancer Foundation ($11M) funding for early detection in pancreatic, ovarian, and glioblastoma.
5. Bond Financing and Capital Markets: Capital raised through municipal bond markets, including a $1.29B preliminary bond offering filed to finance the planned 300-bed standalone cancer hospital and a $141.1M IT systems overhaul.

Pricing tiers

Go-to-market motion4 records

Distribution channels8 records

Marketing channels9 records

Core offering

Dana-Farber Cancer Institute is an NCI-Designated Comprehensive Cancer Center that provides specialized adult and pediatric cancer care across 152 cancer types and conditions, supported by more than 1,200 active clinical trials, an open-source AI clinical-trial matching platform (MatchMiner), and an integrated electronic medical record shared with Brigham and Women's Hospital and Boston Children's Hospital. Its core deliverables include multidisciplinary oncology treatment (chemotherapy, radiation, surgery, cellular therapies, stem cell transplant), personalized cancer vaccines, early detection and interception, genomic/liquid-biopsy diagnostics, and full-service patient and family support.

Product overview

Dana-Farber Cancer Institute operates a multi-site, platform-style portfolio of cancer-care delivery, research, and digital products organized around a Harvard Medical School–affiliated academic cancer center. Its core offerings are two main campuses (Longwood Medical Area in Boston and Chestnut Hill), a network of community-based satellite cancer centers (Foxborough, Brighton, Merrimack Valley, Milford, South Shore, Londonderry NH, and the upcoming Attleboro location), and an integrated pediatric program (Dana-Farber / Boston Children's Cancer and Blood Disorders Center). On top of this clinical platform it runs a large portfolio of specialty treatment centers and programs — including the Breast Oncology Center, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Hematologic Oncology, Neuro-Oncology, Thoracic, Melanoma, Sarcoma, and Cutaneous centers, plus the Susan F. Smith Center for Women's Cancers and the Centers for Early Detection and Interception — supported by clinical services such as Cellular Therapies (CAR T-cell), Stem Cell Transplantation, the Center for Immuno-Oncology, the Center for Cancer Therapeutic Innovation, the Leonard P. Zakim Center for Integrative Therapies, and the Phyllis F. Cantor Center for Research in Nursing. Digital / software products layer on top of this clinical platform: the Patient Gateway, MyChildren's, and MyBILH Chart portals for adult, pediatric, and Beth Israel-affiliated care; the MatchMiner open-source AI platform for clinical-trial matching; the investigational NeoVax / NeoVaxMI personalized cancer-vaccine program; the BRIDGE-SIC LLM pilot (deployed with HDAI) for summarizing patient goals of care; the FaceAge AI tool for predicting cancer outcomes from facial photographs; the BrightSeq pediatric precision-genomics initiative with Boston Children's and Broad Clinical Labs; the NACHO algorithmic nutrition toolset; and the clinical decision-support / AI radiology tools Dana-Farber investigators are building in response to updated FDA guidance. Around this platform sit funding and access programs such as Dana-Farber Direct Connect, the Jimmy Fund, the Pan-Mass Challenge, and the Jimmy Fund Walk.

Differentiator

Problem solved

Functional benefit

Brands

• Jimmy Fund: Charitable fundraising arm supporting Dana-Farber's cancer research and patient care mission.
• Jimmy Fund Clinic
• Dana-Farber Brigham Cancer Center
• Dana-Farber/Boston Children's Cancer and Blood Disorders Center
• Dana-Farber/New Hampshire Oncology-Hematology

Products and services

• Breast Oncology Center Multidisciplinary adult treatment center for breast cancer, including programs for DCIS, inflammatory, invasive lobular, metastatic, male, pregnancy-associated, older adult, brain metastases, and young-women breast cancer.
• Gastrointestinal Cancer Treatment Center Specialty center treating esophageal, gastric, colorectal, liver, neuroendocrine/carcinoid, pancreatic, biliary, and young-onset colorectal cancers, including an Older Adults With Gastrointestinal Cancer Program.
• Genitourinary Cancer Treatment Center Specialty center treating all types of genitourinary cancers, including prostate, kidney, bladder, and testicular cancers.
• Gynecologic Oncology Program Specialty center treating all types of gynecologic cancers.
• Head and Neck Cancer Treatment Center Specialty center for head and neck cancers, including the Center for Salivary and Rare Head and Neck Cancers and the Thyroid Cancer Center.
• Hematologic Oncology Treatment Center Specialty center for blood cancers, including Lymphoma Program, Center for CLL, Multiple Myeloma Program, Bing Center for Waldenstrom's Macroglobulinemia, Adult Leukemia Program, Adult Histiocyte Disorders Center, OHM Program, BPDCN Center, and Amyloidosis Program.
• Neuro-Oncology Treatment Center Specialty center for brain tumors, including AYA Neuro-Oncology, Brain Metastases, CNS Lymphoma Center, Spinal Tumor Program, and Glioma Patient Support Program.
• Thoracic (Lung) Cancer Treatment Center Specialty center for thoracic cancers, including the Chen-Huang Center for EGFR Mutant Lung Cancers and the Young Lung Cancer Program.
• Susan F. Smith Center for Women's Cancers Cross-disease center integrating Breast Cancer, Gynecologic Cancers, Cancer Genetics and Prevention, and basic research in women's cancers.
• Centers for Early Detection and Interception Multidisciplinary program for individuals at elevated cancer risk; includes Blood Cancers, Solid Tumors, Multi-Cancer Early Detection Clinic, and genetic syndromes (Lynch, Li-Fraumeni/TP53, BRCA and Related Genes).
• Center for Immuno-Oncology Specialty adult center for immuno-oncology clinical care and research.
• Cellular Therapies Program Adult specialty program providing cellular therapies including CAR T-cell therapy.
• Center for Cancer Therapeutic Innovation (CCTI) Adult specialty center for early-phase clinical trials of novel cancer therapeutics.
• Adult Stem Cell Transplant Program Specialty program delivering adult hematopoietic stem cell transplantation.
• Leonard P. Zakim Center for Integrative Therapies and Healthy Living Patient support center offering integrative therapies such as massage, acupuncture, Reiki, meditation, and other mind/body therapies.
• Dana-Farber / Boston Children's Cancer and Blood Disorders Center Integrated pediatric oncology program jointly operated by Dana-Farber and Boston Children's Hospital, including Blood Disorders Center, Brain Tumor Center, Hematologic Malignancy Center, Solid Tumor Center, CAR T-cell, Stem Cell Transplant, and MIBG Therapy.
• Patient Gateway (Dana-Farber adult patient portal) Secure online portal in partnership with Mass General Brigham for adult patients; allows access to medical records, care-team communication, appointment management, bill payment, virtual visits, and online cost estimates.
• MyChildren's (Dana-Farber pediatric patient portal) Secure online portal in partnership with Boston Children's Hospital for pediatric patients and families to request appointments, view records, send non-urgent messages to the care team, and pay bills.
• MatchMiner Open-source AI platform that matches cancer patients to precision-medicine clinical trials using clinical and genomic data; has facilitated 402 enrollments and reduced median time-to-patient-consent by 55 days.
• NeoVax / NeoVaxMI Personalized Cancer Vaccine Investigational personalized neoantigen cancer-vaccine platform; the modified NeoVaxMI formulation (NeoVax + Montadine + nivolumab + local ipilimumab) generated vaccine-specific immune responses in all 9 melanoma patients in a Phase 1 trial.
• Dana-Farber Direct Connect Access/concierge program that supports patients seeking care at Dana-Farber, including appointments and second opinions.
• Dana-Farber Care Card Reloadable spending card for patients, family members, friends, staff, and visitors for cashless purchases of food and services around Dana-Farber.
• International Patient Services Dedicated program supporting international patients from 130+ countries with travel coordination, financial clearance, interpreter services, and virtual second opinions for advanced cancer care at Dana-Farber.
• Dana-Farber Cancer Clinical Trials Portfolio of more than 1,200 active clinical trials per year across adult and pediatric cancers and blood disorders, offered through Dana-Farber and its clinical partners.
• Firefighters Cancer Navigation Program Specialized cancer navigation program launched in 2025 providing dedicated support and care coordination for firefighters facing cancer diagnoses.
• Veterans Multi-Cancer Early Detection Program Multi-cancer early detection screening program offering a novel cancer screening test to veterans (announced June 30, 2025).

Quantifiable outcome

• #1 cancer hospital in New England; consistently ranked by U.S. News & World Report 2025-2026
• +9 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability17 records

Feature5 records

Partnerships

36 partnerships are on record, tiered flagship, core, major and minor.

• Brigham and Women's HospitalflagshipStrategic or Co-development PartnerClinical partner forming the Dana-Farber Brigham Cancer Center; provides inpatient hospital for adult oncology patients and shares the Patient Gateway portal. Outpatient care occurs at Dana-Farber's Longwood campus, while inpatient adult care takes place at Brigham and Women's Hospital, with the buildings connected by bridges.
• Boston Children's HospitalflagshipStrategic or Co-development PartnerForms the integrated Dana-Farber/Boston Children's Cancer and Blood Disorders Center for pediatric oncology and blood disorders. Boston Children's provides inpatient pediatric care and shares the MyChildren's patient portal.
• Beth Israel Deaconess Medical Center (Beth Israel Lahey Health)flagshipStrategic or Co-development PartnerClinical collaboration partner for the planned 300-bed standalone adult cancer hospital at One Joslin Place, Longwood; the future hospital will operate through this clinical collaboration and connect with Harvard Medical Faculty Physicians. The hospital is part of a $1.8B project with Beth Israel Lahey Health, expected to open in 2031.
• Harvard Medical SchoolflagshipStrategic or Co-development PartnerTeaching affiliate; supports extensive participation by professional staff in medical education, clinical training, and pre/postdoctoral research training. Elective courses in adult and pediatric oncology offered through Dana-Farber.
• Mass General BrighamflagshipStrategic or Co-development PartnerHealth system partner; shares the Patient Gateway portal and supports Dana-Farber adult oncology services. Dana-Farber and Mass General Brigham agreed to collaborate on physician assistants following dispute over inpatient oncology employment arrangements. Also co-led the PROTEUS Phase 3 trial of apalutamide.
• 10x GenomicscoreTechnology or IntegrationMulti-year collaboration to analyze tumor samples from hundreds of patients with major solid cancer types using the Chromium Flex single cell assay and Xenium spatial platform; aims to identify biomarkers for treatment response/resistance and develop a clinical reporting framework for emerging precision oncology treatments. 10x Genomics also plans to build a CLIA-certified laboratory.
• Break Through CancercoreStrategic or Co-development PartnerFunder and research collaboration partner; part of a $50M initiative involving five top cancer research centers to foster collaboration and real-time data sharing on deadly cancers such as pancreatic, ovarian, and glioblastoma. Dana-Farber received over $11M from this initiative. Break Through Cancer also led a multi-site CD123-targeted Phase 1/2 trial in AML.
• HyundaimajorGTM or Marketing PartnerPresenting sponsor of the 38th Annual Jimmy Fund Walk for Dana-Farber (scheduled October 4, 2026); the event aims to collect $10 million in 2026 and has raised over $197 million in its 37-year history.
• Pan-Mass ChallengeflagshipGTM or Marketing PartnerSignature annual cycling fundraiser; raised $78M for Dana-Farber in its most recent event, with over $1.125B raised since 1980. PMC is the largest single contributor to Dana-Farber and accounts for 67% of The Jimmy Fund's revenue.
• Akeno (Break Through Cancer)minorStrategic or Co-development PartnerRevolution Medicines (daraxonrasib) Phase 3 RASolute 302 trial led by Dana-Farber with investigators; 500 patients; 60% reduction in risk of death; 13.2 months median OS vs 6.6-6.7 months for chemotherapy in metastatic pancreatic cancer.
• Agenus Inc.minorStrategic or Co-development PartnerPhase 1b C-800-01 study (BOT+BAL) in MSS metastatic colorectal cancer; Dr. Benjamin L. Schlechter of Dana-Farber delivering the ESMO GI 2026 poster presentation on July 2, 2026, featuring three-year survival data from 123 patients.
• Akeso and INOVIOcoreStrategic or Co-development PartnerClinical trial collaboration and supply agreement to evaluate cadonilimab (Akeso's PD-1/CTLA-4 bispecific) in combination with INO-5412 (INOVIO's DNA immunotherapy) for glioblastoma, as part of the INSIGhT Phase 2 adaptive platform trial sponsored by Dana-Farber Cancer Institute. Dosing expected to begin H2 2026.
• JNCCN (Journal of the National Comprehensive Cancer Network)minorOthersPublished a randomized controlled trial conducted by Dana-Farber on targeted nudges to clinicians and patients that significantly increased serious illness conversations between cancer patients and oncologists (79% higher odds of advance care planning within 60 days).
• Precede BiosciencesminorStrategic or Co-development PartnerThree supporting studies presented at AACR 2026 conducted in collaboration with Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, Genentech, and Emory University School of Medicine demonstrated the Precede Bio Insight liquid biopsy's ability to predict therapeutic response and resistance in breast and prostate cancer.
• TAG1 Inc.minorStrategic or Co-development PartnerStrategic collaboration with the Molecular Cancer Imaging Facility at Dana-Farber to accelerate development of targeted alpha therapies for cancer treatment; TAG1 supplies its proprietary Lead-212 generator technology to enable pre-clinical and clinical research.
• Brigham and Women's Hospital (PA collaboration)coreStrategic or Co-development PartnerAgreed to collaborate on physician assistants following a dispute over their employment arrangement in inpatient oncology. PAs are employed by Dana-Farber but contracted to work in Brigham's inpatient oncology units; described as a 'conscious uncoupling' approach.
• C-Further ConsortiumminorStrategic or Co-development PartnerInternational consortium for childhood cancer therapeutics supported by $40M (£30M) initial budget with core partners Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity. CF-012 program for Ewing sarcoma partnered with UVA Comprehensive Cancer Center, Dana-Farber, and Mass General Brigham.
• St. Jude Children's Research HospitalminorStrategic or Co-development PartnerLargest-ever single-cell study of pineoblastoma tumors in collaboration with Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Uppsala University; published in Cancer Cell.
• Zapata QuantumminorStrategic or Co-development PartnerNature Biotechnology paper on quantum-enabled drug discovery conducted in collaboration with Dana-Farber Cancer Institute, University of Toronto, and Insilico Medicine; named one of Nature Biotechnology's Top 10 Papers of 2025.
• Burjeel Cancer Institute (Burjeel Holdings)minorStrategic or Co-development PartnerLaunched the UAE's first accredited fellowship program in oncology in partnership with Harvard Medical School and Dana-Farber Cancer Institute; serves over 5,000 oncology patients annually with 10,000+ radiotherapy sessions.
• Sheba Medical Center (ARC Landing Boston)minorStrategic or Co-development PartnerStartup accelerator ARC Landing Boston in partnership with Massachusetts Governor Maura Healey; six Israeli startups providing a U.S. market gateway, working with local healthcare facilities including Boston Medical Center and Dana-Farber Cancer Institute.
• BEEAH Group (Renzo Piano Building Workshop)minorStrategic or Co-development PartnerJawaher Boston Medical District healthcare facility in Sharjah, UAE, developed in collaboration with Mass General Brigham and Dana-Farber Cancer Institute; integrates cutting-edge medical technology with sustainable, patient-centric design.
• Merck (KEYTRUDA/pembrolizumab)coreStrategic or Co-development PartnerDana-Farber led the Phase 3 LITESPARK-022 trial (1,841 patients) supporting FDA approval of pembrolizumab (Keytruda) in combination with belzutifan (Welireg) for adjuvant treatment of adults with renal cell carcinoma at intermediate-high/high risk of recurrence following nephrectomy.
• Salk InstituteminorStrategic or Co-development PartnerCollaboration on a vitamin D analog (paricalcitol) clinical trial in 36 patients with previously untreated metastatic pancreatic cancer; demonstrated a significant survival boost when combined with chemotherapy by reducing inflammation and fibroblasts in tumors.
• University of Texas Health Science Center and MD Anderson Cancer CenterminorStrategic or Co-development PartnerLarge-scale study at European Society of Human Genetics conference analyzing genetic ancestry's influence on tumor mutations and cancer survival across more than 30,000 patients with five major cancer types.
• Boston Children's Hospital and Broad Clinical Labs (BrightSeq)coreStrategic or Co-development PartnerBrightSeq collaborative initiative to improve pediatric cancer diagnostics through precision genomics; will develop and implement novel clinical diagnostic assays for rare pediatric cancers, focusing on genomic analysis and liquid biopsies.
• Memorial Sloan Kettering (Cancer AI Alliance)coreStrategic or Co-development PartnerFounding member of the Cancer AI Alliance (CAIA), a collaborative initiative involving four NCI-designated cancer centers and major technology companies leveraging diverse datasets and federated learning while safeguarding patient data privacy.
• Johns Hopkins (Cancer AI Alliance)coreStrategic or Co-development PartnerFounding member of the Cancer AI Alliance along with MSK and other NCI-designated cancer centers; new AI projects fine-tuning models to predict patient outcomes and analyzing rare brain cancer subtypes using multicenter data.
• Aditxt (Ignite Proteomics)minorStrategic or Co-development PartnerPeer-reviewed study in npj Precision Oncology led by Dana-Farber Cancer Institute evaluating Ignite's Reverse Phase Protein Array (RPPA) platform for predicting outcomes in metastatic breast cancer patients treated with trastuzumab deruxtecan (T-DXd/Enhertu).
• 4D Path (DAD-IO Trial)minorStrategic or Co-development Partner4D Path participates as an exploratory biomarker collaborator in the Phase II DAD-IO clinical trial led by Dana-Farber and supported by Gilead Sciences; uses Q-Plasia OncoReader (QPOR) platform to analyze pre-treatment biopsies for predictive biomarkers in bladder cancer.
• U.S. Food and Drug Administration (FDA)majorOthersUpdated FDA guidance on January 6 clarifying clinical decision-support software criteria; Dana-Farber expert commented on LLM applications in radiology and pathology enabled by the update.
• Harvard Medical School (Investigators)coreStrategic or Co-development PartnerPhase 1 clinical trial at Harvard Medical School, Dana-Farber Cancer Institute, and Mass General Brigham tested an oncolytic virus therapy on 41 patients with recurrent glioblastoma; the therapy is made from a genetically altered herpes simplex virus.
• Boston College Swim and Dive / Swim Across AmericaminorGTM or Marketing PartnerHosted Swim Across America charity event to raise funds for cancer research at Dana-Farber Cancer Institute and Mass General Brigham oncology research.
• Akari Therapeutics (SAB)minorOthersDr. Prafulla Gokhale, Director at Dana-Farber Cancer Institute and head of the Experimental Therapeutics Core, appointed to Akari Therapeutics Scientific Advisory Board to support development of AKTX-101.
• Sanofi / Boston Globe Health Equity SummitminorGTM or Marketing Partner2026 Health Equity Summit presented by Sanofi with sponsorship from CareQuest Institute for Oral Health, Dana-Farber Cancer Institute, Eliot, and Johnson & Johnson; convenes health experts to discuss reducing health disparities and fostering inclusive care.
• Boston Red Sox (Jimmy Fund)flagshipGTM or Marketing PartnerLongstanding Jimmy Fund-Boston Red Sox partnership dating back to the establishment of the Jimmy Fund; part of the broader Yawkey family relationship spanning more than 75 years including early support for founder Dr. Sidney Farber.

Scale indicators15 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Memorial Sloan Kettering Cancer Center: NCI-designated Comprehensive Cancer Center in New York offering adult and pediatric oncology care, 1,000+ clinical trials, and precision-oncology research; fellow Cancer AI Alliance founding member with Dana-Farber. Closest comparable in mission, scale, and trial leadership.
• MD Anderson Cancer Center: University of Texas NCI-designated Comprehensive Cancer Center, the largest U.S. cancer center by patient volume and research funding; competes head-to-head with Dana-Farber for top USNWR rankings, sponsored trials, and international patients.
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center and fellow Cancer AI Alliance founding member; matches Dana-Farber in translational research output, Phase 3 trial leadership, and academic cancer center positioning.
• Fred Hutchinson Cancer Center: Seattle-based NCI-designated Comprehensive Cancer Center and the original home of bone-marrow transplantation; co-investigator with Dana-Farber on the Precede Bio liquid biopsy AACR 2026 studies and comparable in trial/research intensity.
• Mayo Clinic Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center within Mayo Clinic, with a multi-site, multi-state clinical footprint comparable to Dana-Farber's Massachusetts/New Hampshire network and similar premium brand positioning.
• Stanford Cancer Institute: NCI-designated Comprehensive Cancer Center at Stanford Medicine, with deep precision-oncology, immuno-oncology, and AI-research capabilities directly comparable to Dana-Farber's research portfolio.
• Moffitt Cancer Center: Florida-based NCI-designated Comprehensive Cancer Center with a large clinical-trial portfolio and a top-50 USNWR ranking; overlaps with Dana-Farber in adult oncology focus and large-scale trial operations.
• Roswell Park Comprehensive Cancer Center: America's first cancer center and an NCI-designated Comprehensive Cancer Center in Buffalo, NY; comparable in mission, scope of adult oncology services, and emphasis on translational research.

Broad incumbents

• Mass General Brigham Cancer Institute (Massachusetts General Hospital): The broader Boston-based health system partner; shares the Patient Gateway portal with Dana-Farber and co-led the PROTEUS trial. Functions as both a partner and a regional competitor for adult oncology patients and research funding.

Emerging players

• Burjeel Cancer Institute (Burjeel Holdings): UAE-based oncology provider that recently launched the region's first accredited oncology fellowship in partnership with Harvard Medical School and Dana-Farber; a regional/emerging player building Dana-Farber-affiliated capacity in the Middle East.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/danafarber
• Facebookfacebook.com/danafarbercancerinstitute
• LinkedInlinkedin.com/company/dana-farber-cancer-institute

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries2 records

Funding overview

Funding rounds10 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dana-Farber Cancer Institute